Robotic surgery is no longer a novelty. The enormous technological advantages of surgical robots have prompted many large hospitals in China to accelerate their adoption of them.
The da Vinci Surgical System is an endoscopic surgical instrument control system widely used in clinical departments such as urology, general surgery, gynecology, and cardiothoracic surgery. Compared to traditional minimally invasive surgery, surgical robots are more precise and meticulous, offering advantages in terms of operation and hospitalization time, reduced blood loss, lower complication rates, and faster postoperative recovery, significantly improving patients' postoperative quality of life.
For example, surgical robots have a clear advantage in prostate cancer removal. With conventional resection methods, some patients lose their sexual function because the sexual nerves are extremely delicate and cannot be observed with ordinary medical instruments. Surgical robots, however, allow a higher percentage of patients to retain their right to sexual well-being.
In addition, robotic surgery significantly reduces bleeding, which helps alleviate the growing blood shortage.
Some domestic companies have achieved remarkable success by bypassing areas where they have an advantage, such as the "da Vinci robot," and instead focusing on fields like orthopedics, neurosurgery, and interventional surgery. Tianzhihang's Tianji orthopedic robot and Baihuiweikang's "Ruimi" neurosurgical robot have both successfully passed the Class III medical device review and are increasingly expanding the functional boundaries of surgical robots.
Numerous long-time adventurers have flocked to this market worth hundreds of billions. Traditional leading companies, such as Medtronic, Johnson & Johnson, Stryker, Zimmer Biomet, and Smith & Nephew, have all completed their layout in the field of surgical robots through acquisitions and mergers, integrating them with their own systems. They are constantly expanding their boundaries and vying for market share, intending to compete with da Vinci in multiple fields.
Although China's surgical robot market has completed its early market education, its technological competitiveness in high-end surgical robot diagnostic equipment is weak due to limitations in technological innovation capabilities and incomplete innovation and industrial chains. Domestic companies such as Tinavi, Baihui Weikang, and Miaoshou Robotics have entered this field.
